Investor Relations Center
Company profile
Medinice S.A. conducts research and development of innovative medical devices in cardiology. Its main projects include PacePress (a compression band used after implantation of cardiac devices), AtriClamp (a clamp for left atrial appendage closure), and CoolCryo (a cryoapplicator for cardiac surgical ablation). The Company focuses on prototype development, preclinical and clinical testing, and obtaining patents.
Stock price
Medinice S.A. shares have been listed on the Main Market of the Warsaw Stock Exchange since December 30, 2020. Previously, on September 25, 2018, the Company debuted on the NewConnect market.
Sector: medical equipment and supplies
ISIN: PLMDNCE00016
Ticker: ICE.WA
Latest news
- 2026-02-13
FDA Grants Clearance for CoolCryo Enabling U.S. Market Entry
Medinice S.A. received FDA 510(k) clearance on February 13, 2026, for the medical device CoolCryo, confirming its equivalence to a reference device. This marks a key step in bringing CoolCryo to the U.S. market for treating heart arrhythmias via cryoablation.
- 2025-11-07
Letter to Shareholders regarding the December 3, 2025 EGM
Medinice S.A. announces that the company continues to execute its key projects and commercialization activities in line with the adopted strategy. The investment agreement with the fund remains in effect, and an investor meeting summarizing 2025 will be held soon.
Events and presentations
- March 12, 2026
Medinice CEO in BIZNES24’s 'Company Under the Spotlight' Interview [PL]
- May 30, 2025
CoolCryo video for the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2025 conference
Previous events
Latest company reports
- The latest periodic report2026-03-18 17:16
Consolidated annual report for 2025 RR
- The latest current report2026-03-30 15:38 | ESPI 10/2026
Assimilation of the Issuer's shares
- 2026-03-30 09:30ESPI | 9/2026Admission and introduction to stock exchange trading of series N, L2, L3 shares
- 2026-03-06 20:49ESPI | 8/2026Submission of a pre-submission (Q-Sub) application to the FDA in the AtriClamp project See more reports
Additional information
- General Meetings
Learn more
Corporate documentsLearn more
- Investor's calendarTimetable for the Release of Periodic Reports in 2025
- Annual report for 2025: Mar 18, 2026
- Report for Q1-2026: May 8, 2026
- Report for H1-2026: Sept 11, 2026
- Report for Q3-2026: Nov 6, 2026
Shareholder structure
Corporate presentationApril 2026
Equity research reports
Leadership TeamLearn more
- Dividend policyOn July 1, 2019, the Management Board of Medinice S.A. adopted a resolution regarding the Company’s dividend policy. In the event that the Company generates a profit eligible for distribution, the Management Board intends to annually submit a proposal to the Ordinary General Meeting for the payment of a dividend, based on the following parameters:
- Profit for distribution and total dividend payout
- 15 - 50 million PLN: at least 50% of profit to be distributed
- 50 - 100 million PLN: at least 60% of profit to be distributed
- Above 100 million PLN: at least 75% of profit to be distributed
Capital Group Structure
Investor contact
Piotr Uchman
Investor Relations Manager
We Care About Your Privacy
Medinice S.A. uses cookies to improve and customize users experience on our website. By selecting 'Accept', you consent to the use of all cookies that gather and use information about your interactions with our site to provide personalized content and enhance your digital experience. Please read our Privacy Policy for more information.